Abstract:Background The RNA-binding protein Musashi-2 (MSI2) has been implicated in the tumorigenesis and tumor progression of some human cancers. MSI2 has also been reported to suppress tumor epithelial-to-mesenchymal transition (EMT) progression in breast cancer, and low MSI2 expression is associated with poor outcomes for breast cancer patients; however, the underlying mechanisms have not been fully investigated. This study investigated the expression and phenotypic functions of two major alternatively spliced MSI2 isoforms (MSI2a and MSI2b) and the potential molecular mechanisms involved in triple-negative breast cancer (TNBC) progression. Methods The Illumina sequencing platform was used to analyze the mRNA transcriptomes of TNBC and normal tissues, while quantitative reverse transcription-polymerase chain reaction and immunohistochemistry validated MSI2 isoform expression in breast cancer tissues. The effects of MSI2a and MSI2b on TNBC cells were assayed in vitro and in vivo. RNA immunoprecipitation (RIP) and RNA sequencing were performed to identify the potential mRNA targets of MSI2a, and RIP and luciferase analyses were used to confirm the mRNA targets of MSI2. Results MSI2 expression in TNBC tissues was significantly downregulated compared to that in normal tissues. In TNBC, MSI2a expression was associated with poor overall survival of patients. MSI2a overexpression in vitro and in vivo inhibited TNBC cell invasion as well as extracellular signal-regulated kinase 1/2 (ERK1/2) activity. However, MSI2b overexpression had no significant effects on TNBC cell migration. Mechanistically, MSI2a expression promoted TP53INP1 mRNA stability by its interaction with the 3′-untranslated region of TP53INP1 mRNA. Furthermore, TP53INP1 knockdown reversed MSI2a-induced suppression of TNBC cell invasion, whereas ectopic expression of TP53INP1 and inhibition of ERK1/2 activity blocked MSI2 knockdown-induced TNBC cell invasion. Conclusions The current study demonstrated that MSI2a is the predominant functional isoform of MSI2 proteins in TNBC, that its downregulation is associated with TNBC progression and poor prognosis and that MSI2a expression inhibited TNBC invasion by stabilizing TP53INP1 mRNA and inhibiting ERK1/2 activity. Overall, our study provides new insights into the isoform-specific roles of MSI2a and MSI2b in the tumor progression of TNBC, allowing for novel therapeutic strategies to be developed for TNBC.

Musashi-2 is a Prognostic Marker for the Survival of Patients with Cervical Cancer.

Expression of Musashi2 gene in de novo acute myeloid leukemia and its clinical implications

DSG2 and C-Myc Interact to Regulate the Expression of ADAM17 and Promote the Development of Cervical Cancer

196P Expression of Musashi-1 Protein and Its Implications in Progression and Prognosis of Gastric Cancer

Inhibition of RNA-Binding Protein Musashi-1 Suppresses Malignant Properties and Reverses Paclitaxel Resistance in Ovarian Carcinoma

Stem-cell-abundant Proteins Nanog, Nucleostemin and Musashi1 Are Highly Expressed in Malignant Cervical Epithelial Cells

Prognostic Significance of the Musashi-2 (MSI2) Gene in Childhood Acute Lymphoblastic Leukemia

Increased Musashi 2 Expression Indicates a Poor Prognosis and Promotes Malignant Phenotypes in Gastric Cancer

High Expression Of Musashi-2 Indicates Poor Prognosis In Adult B-Cell Acute Lymphoblastic Leukemia

Msi1 Promotes Tumor Progression by Epithelial-to-mesenchymal Transition in Cervical Cancer.

Msi1 Promotes Tumor Growth and Cell Proliferation by Targeting Cell Cycle Checkpoint Proteins P21, P27 and P53 in Cervical Carcinomas

Msi-1 is a Predictor of Survival and a Novel Therapeutic Target in Colon Cancer

Musashi2 as a novel predictive biomarker for liver metastasis and poor prognosis in colorectal cancer.

Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation

MSI2 Knockdown Represses Extrahepatic Cholangiocarcinoma Growth and Invasion by Inhibiting Epithelial-Mesenchymal Transition.

Musashi-1 Enhances Glioblastoma Cell Migration and Cytoskeletal Dynamics through Translational Inhibition of Tensin3

RNA-binding Protein MSI2 Isoforms Expression and Regulation in Progression of Triple-Negative Breast Cancer

Effect of RNA-binding Protein MSI2 Deficiency on Progression in Triple-Negative Breast Cancer Via Stabilizing TP53INP1.

MicroRNA-140-5p Targets Insulin Like Growth Factor 2 Mrna Binding Protein 1 (IGF2BP1) to Suppress Cervical Cancer Growth and Metastasis.

The oncogene Musashi1 encodes novel miRNAs in breast cancer

Musashi1 Promotes Tumor Metastasis and is a Prognostic Marker for Renal Carcinoma